Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of once-daily omiganan topical gel versus vehicle in severe papulopustular rosacea
2015-002919-15Phase 3Completed
- Sponsor
- Cutanea Life Sciences
- Start
- Sep 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omiganan in papulopustular rosacea and rosacea (3 arms), sponsored by Cutanea Life Sciences. Primary endpoints: Change from baseline in inflammatory lesion count and Investigator Global Assessment success. Started Sep 2015; status: completed.
02
Drugs
omiganan
03
Conditions
papulopustular rosacearosacea
Beyond the preview
Go deeper on 2015-002919-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002919-15.